Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Shares of Moderna have doubled after its cancer vaccine trial with Merck met key endpoints.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 21.
Source diversity sample: Axios · Clinical Trials Arena · Yahoo Finance · The Denver Post · Business Wire · The New York Times.
How this dossier is built: methodology · AI policy · corrections.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
The Phase 3 INTerpath-001 trial of Intismeran Autogene Plus KEYTRUDA® has met its endpoints of recurrence-free survival and distant metastasis-free survival in patients with completely resected Stage IIB-IV melanoma. The trial was conducted by Merck and Moderna.
The Denver Post and Yahoo Finance both note that Moderna's stock has surged. Business Wire and The New York Times both report that the vaccine prevents melanoma from returning.
The trial's full results have not yet been published. The specific details of the trial's methodology and patient outcomes are not yet available.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4h ago.
Coverage (7)
- Moderna and Merck shares soar on mRNA cancer vaccine Axios · 2h ago
- MSD and Moderna eye cancer vaccine market debut on Phase III melanoma score Clinical Trials Arena · 6h ago
- Moderna, Merck Report Positive Phase 3 Trial Results of Melanoma Drug; Moderna Shares Jump Over 100% Yahoo Finance · 6h ago
- Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test The Denver Post · 6h ago
- Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means Yahoo Finance · 6h ago
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melano Business Wire · 7h ago
- Moderna and Merck Say mRNA Vaccine Prevents Melanoma From Returning The New York Times · 7h ago
Answered
What is the name of the cancer vaccine?
The vaccine is called Intismeran Autogene Plus KEYTRUDA®.
What stage of melanoma was the vaccine tested on?
The vaccine was tested on patients with completely resected Stage IIB-IV melanoma.
What are the endpoints that the vaccine met?
The vaccine met the endpoints of recurrence-free survival and distant metastasis-free survival.
Topics
From around our network
Related trends
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna and Merck report success in a late-stage melanoma trial for their personalized mRNA vaccine, triggering a surge in Moderna shares.
Why cancer, not cost of living, may be the biggest issue in Iowa’s midterm elections
Iowa voters are prioritizing cancer over cost of living in the upcoming midterm elections.
‘Mismatched’ vaccine being rolled out against Ebola outbreak
Public health agencies are deploying an Ebola vaccine that does not perfectly match the circulating virus strain while preparing new clinical trials.
FDA approves Replimune melanoma drug previously rejected twice
Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
First poo transplant to treat food allergy in people has ‘exciting’ results
A small trial of fecal transplants shows promise in treating food allergies, but the method is not yet widely accepted.
F.D.A. Approves Moderna’s mRNA Flu Vaccine
The FDA's approval of Moderna's mRNA flu vaccine marks a significant shift in seasonal flu prevention, particularly for older adults.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.